Rapid diagnostic pathways for suspected colorectal cancer: views of primary and secondary care clinicians on challenges and their potential solutions
Maria Theresa Redaniel(University of Bristol), Julia Wade(University of Bristol), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), Matthew J Ridd(University of Bristol), Mona Jeffreys(University of Bristol), Richard M. Martin(Drug Safety Research Unit)
Cited by 24
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Effect of Infant Feeding on the Risk of Obesity Across the Life Course: A Quantitative Review of Published Evidence
|PEDIATRICS|2005|1.2k
Birth Weight and Risk of Type 2 Diabetes
|JAMA|2008|952
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|728
Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis
|Nature Communications|2020|694